NKGN

Nkgen Biotech Inc. (NKGN) | Rumor.io

Nkgen Biotech

NKGN

Attention (50-day avg)0%

Attention rank (50-day avg)#3,955

Bullish sentiment (50-day avg)60%

Price to earnings ratio-0.01

Market capitalization1.6M

Earnings per share-1.33

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about NKGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

May 12

$NKGN is gaining momentum and expected to take off with any positive news.
Investors are advised to give the company a serious look for potential high rewards.
NKGen Biotech's future potential is being closely watched, with some speculating about the CEO's plans.

Generated by AI

Sentiment

Of the messages about NKGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	75% new	82.98% -6.02
Bearish	—	0% 0	25% -75	17.02% +6.02

Bullish· Mar 4

$NKGN's NKmax deal and FDA approval process for its cell therapy are major catalysts for the company's growth.
The company's history of overcoming challenges, such as being delisted and regaining NASDAQ status, suggests it can recover from current setbacks.
$NKGN's innovative NK cell therapy has shown potential clinical progress, including a compassionate use dose in a stroke patient, indicating a promising future for the company.

Bearish· Jul 18

$NKGN has a history of ripping after gap ups, but then relapsing and failing to hold its gains.
The company's need for cash and its potential for a buyout at a lower price than previously expected are contributing to bearish sentiment.
$NKGN's price action is expected to be negatively impacted by the company's need to raise capital and the lack of a strong catalyst to drive the stock higher.

Generated by AI

Topics

Of the messages about NKGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	100%
Analysts	—	—	0%	0%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	0%

Announcements· Feb 21

NKGen Biotech administered the first dose of troculeucel, its autologous NK cell therapy, to a frontotemporal dementia (FTD) patient under an FDA-cleared compassionate use program.
The administration is part of a study with the David Geffen School of Medicine at UCLA to explore troculeucel's potential in reducing neuroinflammation and tau levels in FTD patients.
CEO Paul Y. Song highlighted troculeucel's ability to cross the blood-brain barrier, a key factor in its potential to treat FTD and related disorders.

Technical Analysis· Feb 21

$NKGN has shown a 10% gain since it first appeared on the radar, with RSI and MACD indicators suggesting potential sustainability of momentum.
$NKGN is up since landing on the scanner, with initial momentum and potential for breaking overhead resistance levels with conviction.
$NKGN is showing signs of a further gap up, with a 10% increase since landing on the scanner, and is ready to potentially break above $0.68 and reach $0.70+.

Generated by AI

Community

Of the messages about NKGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	23.81%	67.95%
Newcomers	—	0%	76.19%	32.05%

Also Discussed

Investors talking about NKGN also mention

#	Name	Attention
1	VIGL - Vigil Neuroscience, Inc.	——
2	LENZ Therapeutics, Inc.LENZ	0%new
3	Aptorum Group Ltd.APM	0%new
4	EGOX - Next.e.GO N.V. Ordinary Shares	——
5	SPEC - Spectaire Holdings Inc.	——
6	BitFuFu Inc. Class A Ordinary SharesFUFU	0%0
7	PaxMedica Inc.PXMD	0%0
8	SGD - Safe and Green Development Corporation	——
9	MKDWELL Tech Inc.MKDW	0%+0
10	ROI - RiskOn International, Inc.	——

Nkgen Biotech Inc.

Healthcare
Biotechnology

Nkgen Biotech Inc. is a biotechnology firm primarily focused on the research, development, and commercialization of innovative cellular therapies. The company aims to leverage its cutting-edge technologies to advance treatments for various diseases, enhancing medical solutions through its proprietary approaches. With a strong emphasis on harnessing natural killer (NK) cells' therapeutic potential, Nkgen Biotech is at the forefront of immunotherapy initiatives particularly targeting cancer and other serious ailments. The firm impacts the broader healthcare and life sciences sectors by pushing the boundaries of personalized medicine and offering potentially transformative advances in disease management. As biotechnology plays a critical role in addressing unmet medical needs, Nkgen Biotech Inc. stands as an influential entity within this dynamic and evolving landscape. With ongoing research and robust development pipelines, it is positioned to contribute significantly to the future of medical treatment innovations.

Website

Location

3001 Daimler Street

Santa Ana, CA, 92705

United States

Social

What share of all stock conversation is about NKGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

May 12

$NKGN is gaining momentum and expected to take off with any positive news.
Investors are advised to give the company a serious look for potential high rewards.
NKGen Biotech's future potential is being closely watched, with some speculating about the CEO's plans.

Generated by AI

Sentiment

Of the messages about NKGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	75% new	82.98% -6.02
Bearish	—	0% 0	25% -75	17.02% +6.02

Bullish· Mar 4

$NKGN's NKmax deal and FDA approval process for its cell therapy are major catalysts for the company's growth.
The company's history of overcoming challenges, such as being delisted and regaining NASDAQ status, suggests it can recover from current setbacks.
$NKGN's innovative NK cell therapy has shown potential clinical progress, including a compassionate use dose in a stroke patient, indicating a promising future for the company.

Bearish· Jul 18

$NKGN has a history of ripping after gap ups, but then relapsing and failing to hold its gains.
The company's need for cash and its potential for a buyout at a lower price than previously expected are contributing to bearish sentiment.
$NKGN's price action is expected to be negatively impacted by the company's need to raise capital and the lack of a strong catalyst to drive the stock higher.

Generated by AI

Topics

Of the messages about NKGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	100%
Analysts	—	—	0%	0%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	0%

Announcements· Feb 21

NKGen Biotech administered the first dose of troculeucel, its autologous NK cell therapy, to a frontotemporal dementia (FTD) patient under an FDA-cleared compassionate use program.
The administration is part of a study with the David Geffen School of Medicine at UCLA to explore troculeucel's potential in reducing neuroinflammation and tau levels in FTD patients.
CEO Paul Y. Song highlighted troculeucel's ability to cross the blood-brain barrier, a key factor in its potential to treat FTD and related disorders.

Technical Analysis· Feb 21

$NKGN has shown a 10% gain since it first appeared on the radar, with RSI and MACD indicators suggesting potential sustainability of momentum.
$NKGN is up since landing on the scanner, with initial momentum and potential for breaking overhead resistance levels with conviction.
$NKGN is showing signs of a further gap up, with a 10% increase since landing on the scanner, and is ready to potentially break above $0.68 and reach $0.70+.

Generated by AI

Community

Of the messages about NKGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	23.81%	67.95%
Newcomers	—	0%	76.19%	32.05%

Nkgen Biotech

Social

May 12

Sentiment

Bullish· Mar 4

Bearish· Jul 18

Topics

Announcements· Feb 21

Technical Analysis· Feb 21

Community

Also Discussed

Nkgen Biotech Inc.

Company Information

Location

Social

May 12

Sentiment

Bullish· Mar 4

Bearish· Jul 18

Topics

Announcements· Feb 21

Technical Analysis· Feb 21

Community

Also Discussed